$SMMT
Summit Therapeutics Inc. Stock $smmt

$smmt Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000159929822000118 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$220.0K	$1.309M
YoY Change	-100.0%	-83.19%	623.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.578M	$5.573M	$5.662M
YoY Change	-2.6%	-1.57%	-17.29%
% of Gross Profit
Research & Development	$5.386M	$17.05M	$19.94M
YoY Change	-76.69%	-14.51%	45.29%
% of Gross Profit
Depreciation & Amortization	$305.0K	$310.0K	$337.0K
YoY Change	-7.01%	-8.01%	-15.11%
% of Gross Profit
Operating Expenses	$11.83M	$22.62M	$25.61M
YoY Change	-55.01%	-11.65%	19.48%
Operating Profit		-$16.94M	-$19.49M
YoY Change		-13.07%	15.02%
Interest Expense	-$8.076M	$692.0K	$0.00
YoY Change	264.44%
% of Operating Profit
Other Income/Expense, Net	$9.146M	-$4.445M	-$113.0K
YoY Change	685.74%	3833.63%	-86.83%
Pretax Income	-$19.23M	-$21.39M	-$19.60M
YoY Change	-29.04%	9.11%	10.11%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$19.23M	-$21.39M	-$19.60M
YoY Change	-29.04%	9.11%	10.46%
Net Earnings / Revenue		-9720.45%	-1497.25%
Basic Earnings Per Share		-$0.14	-$0.20
Diluted Earnings Per Share	-$0.10	-$0.14	-$0.20
COMMON SHARES
Basic Shares Outstanding	201.3M shares	98.12M shares	97.45M shares
Diluted Shares Outstanding		148.6M shares	97.45M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$348.6M	$122.0M	$80.25M
YoY Change	385.59%	51.99%	277.28%
Cash & Equivalents	$348.6M	$122.0M	$80.25M
Short-Term Investments
Other Short-Term Assets	$486.0K	$428.0K	$1.191M
YoY Change	-59.53%	-64.06%	-28.55%
Inventory
Prepaid Expenses	$1.504M	$1.622M	$8.409M
Receivables	$349.0K	$140.0K	$2.300M
Other Receivables	$5.766M	$12.96M	$10.07M
Total Short-Term Assets	$656.7M	$137.1M	$102.2M
YoY Change	574.85%	34.15%	142.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$906.0K	$930.0K	$656.0K
YoY Change	30.55%	41.77%	-9.39%
Goodwill	$1.798M	$1.655M	$2.000M
YoY Change	-10.5%	-17.25%	-14.35%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$577.0K	$140.0K
YoY Change	239.41%
Total Long-Term Assets	$7.456M	$18.21M	$26.46M
YoY Change	-53.58%	-31.19%	78.95%
TOTAL ASSETS
Total Short-Term Assets	$656.7M	$137.1M	$102.2M
Total Long-Term Assets	$7.456M	$18.21M	$26.46M
Total Assets	$664.2M	$155.3M	$128.7M
YoY Change	485.82%	20.71%	126.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$355.0K	$1.431M	$5.875M
YoY Change	-91.88%	-75.64%	135.66%
Accrued Expenses	$10.66M	$11.14M	$7.432M
YoY Change	48.17%	49.91%	68.99%
Deferred Revenue	$0.00	$0.00	$7.511M
YoY Change	-100.0%	-100.0%	5.63%
Short-Term Debt	$19.77M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$38.78M	$16.68M	$22.79M
YoY Change	51.36%	-26.8%	54.59%
LONG-TERM LIABILITIES
Long-Term Debt	$494.5M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.429M	$2.424M	$2.690M
YoY Change	-48.52%	-9.89%	18.14%
Total Long-Term Liabilities	$1.429M	$2.424M	$2.690M
YoY Change	-48.52%	-9.89%	18.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.78M	$16.68M	$22.79M
Total Long-Term Liabilities	$1.429M	$2.424M	$2.690M
Total Liabilities	$537.5M	$22.08M	$26.38M
YoY Change	1686.35%	-16.29%	31.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$378.3M	-$359.1M	-$272.4M
YoY Change	26.3%	31.83%	36.75%
Common Stock	$2.110M	$2.013M	$976.0K
YoY Change	115.31%	106.25%	45.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$126.7M	$133.2M	$102.3M
YoY Change
Total Liabilities & Shareholders Equity	$664.2M	$155.3M	$128.7M
YoY Change	485.82%	20.71%	126.28%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$19.23M	-$21.39M	-$19.60M
YoY Change	-29.04%	9.11%	10.46%
Depreciation, Depletion And Amortization	$305.0K	$310.0K	$337.0K
YoY Change	-7.01%	-8.01%	-15.11%
Cash From Operating Activities	$5.191M	-$8.555M	-$23.56M
YoY Change	-156.55%	-63.7%	41.54%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$20.00K	$4.000K
YoY Change	-91.67%	400.0%	-109.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$10.00K	$20.00K	$4.000K
YoY Change	-108.33%	400.0%	-109.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.1M	75.00M	676.0K
YoY Change	41141.87%	10994.23%
NET CHANGE
Cash From Operating Activities	5.191M	-8.555M	-23.56M
Cash From Investing Activities	10.00K	20.00K	4.000K
Cash From Financing Activities	520.1M	75.00M	676.0K
Net Change In Cash	525.3M	66.46M	-22.88M
YoY Change	-6634.72%	-390.42%	37.09%
FREE CASH FLOW
Cash From Operating Activities	$5.191M	-$8.555M	-$23.56M
Capital Expenditures	-$10.00K	$20.00K	$4.000K
Free Cash Flow	$5.201M	-$8.575M	-$23.57M
YoY Change	-157.41%	-63.62%	41.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001599298
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36866
	dei	Entity Registrant Name EntityRegistrantName	Summit Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	37-1979717
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2882 Sand Hill Road, Suite 106
	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	514-7149
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	SMMT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	201321175	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121971000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71791000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1464000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1622000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7161000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	428000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1201000	usd
CY2022Q3	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	12958000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15695000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	137119000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	97312000	usd
CY2022Q3	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	3301000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	930000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	694000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4230000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2790000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1655000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2009000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7952000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	140000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170000	usd
CY2022Q3	us-gaap	Assets Assets	155327000	usd
CY2021Q4	us-gaap	Assets Assets	113374000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1431000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4374000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11141000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7197000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2509000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4125000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1392000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1091000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7939000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	209000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	897000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16682000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25623000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2973000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1691000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2424000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2776000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	22079000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30090000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	201321175	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	201321175	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98039540	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98039540	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2013000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	980000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	493553000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	384049000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3217000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2197000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359101000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299548000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	133248000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	83284000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155327000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113374000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	220000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1309000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	705000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1558000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17049000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19943000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46613000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62245000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5573000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5662000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19165000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15831000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	22622000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	25605000	usd
	us-gaap	Operating Expenses OperatingExpenses	65778000	usd
	us-gaap	Operating Expenses OperatingExpenses	78076000	usd
CY2022Q3	us-gaap	Other Operating Income OtherOperatingIncome	5462000	usd
CY2021Q3	us-gaap	Other Operating Income OtherOperatingIncome	4810000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	13283000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	16379000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16940000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19486000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51790000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60139000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4445000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-113000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7763000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1364000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21385000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19599000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61503000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148582751	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148582751	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98973910	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98973910	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115110095	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115110095	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91771286	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91771286	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21385000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19599000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61503000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-49000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-863000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1020000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	352000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21434000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20462000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60573000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61151000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	51317000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	111000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99889000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	108000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2798000	usd
CY2022Q3	smmt	Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty	570000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-49000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21385000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	133248000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	83284000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	111000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99889000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	295000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9290000	usd
	smmt	Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty	1063000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1020000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	133248000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	119427000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	41000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	41000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	730000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2644000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-863000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19599000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	102298000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79453000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	159000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74841000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1868000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7184000	usd
	smmt	Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty	103000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	352000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61503000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	102298000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61503000	usd
	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	853000	usd
	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	480000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-4271000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	646000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7554000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	960000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	765000	usd
	us-gaap	Depreciation Depreciation	261000	usd
	us-gaap	Depreciation Depreciation	251000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	697000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	768000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9290000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7184000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2387000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2070000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-5006000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1065000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-558000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	82000	usd
	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	3675000	usd
	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	11607000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1336000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1763000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-347000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4817000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3313000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2437000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1098000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-891000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-743000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46773000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63408000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	634000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-634000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-186000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75000000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	111000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	159000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	25000000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	110000000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25000000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	110000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	54000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	295000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1868000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100184000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76655000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2597000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	770000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50180000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13831000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71791000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66417000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121971000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80248000	usd
	us-gaap	Interest Paid Net InterestPaidNet	434000	usd
	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
	smmt	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	smmt	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	41000	usd
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2756000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2756000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2124000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business and Operations and Recent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms "Summit" and the "Company" refer to Summit Therapeutics Inc. and its subsidiaries. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet healthcare needs. The Company's novel pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2022, the Company determined that it will seek partners or a divestiture of ridinilazole, the Company's lead product candidate for treading patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI, as the path forward for the clinical development of the asset. In alignment with this determination, the Company has discontinued its only active study, a pediatric clinical trial evaluating ridinilazole for treating adolescent patients with CDI.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's second product candidate, SMT-738, was announced in May 2021 for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (“CRE”) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered into preclinical development. The Company has two additional discovery-phase assets in its pipeline with undisclosed targets in the therapeutic area of oncology. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intention is to expand its pipeline product portfolio in the therapeutic area of oncology and/or product offerings that are designed to work in harmony with the human gut microbiome. The Company intends to enact this through business development activities, including possible acquisitions and/or collaborations in addition to internal research and discovery efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the Company announced the closing and final results of its previously announced rights offering. The rights offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds from the rights offering were $100,000 from the sale of 103,092,783 shares of the Company's common stock at a price of $0.97 per share. Issuance costs were $111. In connection with the closing of the rights offering, the 2022 Note, which is defined in Note 12, matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 27, 2022, the Company held a Special Meeting of Stockholders (the "Special Meeting") whereby the following matters were submitted to a vote of the Company’s stockholders at the Special Meeting: (i) an amendment to the Company’s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”) to increase the number of shares of the Company’s common stock issuable under the Plan by 8,000,000 shares.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As noted above, on September 28, 2022, the Company determined that it will seek partners or a divestiture of ridinilazole as the path forward for the clinical development of the asset. In alignment with this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">determination, the Company has discontinued its only active study for ridinilazole, a pediatric clinical trial evaluating ridinilazole for treating adolescent patients with CDI.</span></div>
CY2022Q3	smmt	Common Stock Shares Authorized Increase Decrease CommonStockSharesAuthorizedIncreaseDecrease	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Use of Estimates<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. All intercompany accounts and transactions have been eliminated </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in consolidation. The interim financial data as of September 30, 2022, and for the three and nine months ended September 30, 2022 are unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The condensed consolidated balance sheet presented at December 31, 2021 has been derived from the consolidated audited financial statement as of that date. The results of the period are not necessarily indicative of full year results or any other interim period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Summit Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 17, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial results of the Company's activities are reported in United States Dollars.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its unaudited interim financial statements are reasonable and supportable based on the information available as of September 30, 2022, however, the extent to which the COVID-19 pandemic impacts the Company's financial results for the remainder of 2022 and beyond will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21385000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46773000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359101000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121971000	usd
CY2022Q3	smmt	Research And Development Tax Credit Receivable ResearchAndDevelopmentTaxCreditReceivable	16259000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q3	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	2	country
CY2022Q3	us-gaap	Noncurrent Assets NoncurrentAssets	5160000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3484000	usd
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	569000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7939000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8939000	usd
	smmt	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	956000	usd
	smmt	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	4526000	usd
	smmt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	8479000	usd
	smmt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	5532000	usd
	smmt	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	-416000	usd
	smmt	Contract With Customer Liability Foreign Currency Translation ContractWithCustomerLiabilityForeignCurrencyTranslation	-422000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7511000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7939000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8370000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7511000	usd
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q3	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	1224000	usd
CY2021Q3	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	3815000	usd
	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	3730000	usd
	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	11698000	usd
CY2022Q3	us-gaap	Other Operating Income OtherOperatingIncome	5462000	usd
CY2021Q3	us-gaap	Other Operating Income OtherOperatingIncome	4810000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	13283000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	16379000	usd
CY2022Q3	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	12958000	usd
CY2022Q3	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	3301000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15695000	usd
CY2021Q4	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21385000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19599000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-59553000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61503000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148582751	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98973910	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115110095	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91771286	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148582751	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98973910	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115110095	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91771286	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25387813	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18677765	shares
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	60068000	usd
CY2022Q3	us-gaap	Cash Cash	61903000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Cash	71791000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1655000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2009000	usd
CY2022Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16450000	usd
CY2022Q3	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	8498000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2790000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7952000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19963000	usd
CY2021Q4	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	9564000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10399000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	217000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	697000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	256000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	768000	usd
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2756000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2756000	usd
CY2021Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2124000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4230000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1033000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	302000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	785000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3799000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6281000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-881000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	692000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	1497000	usd
	us-gaap	Interest Expense InterestExpense	244000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-83000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-239000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4445000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-113000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7763000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1364000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13797556	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9316631	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3783891	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.96
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11995	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.86
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19318301	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.63
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2963957	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.13
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	527000	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2798000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2644000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9290000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7184000	usd
CY2022Q3	us-gaap	Purchase Obligation PurchaseObligation	0	usd
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd

Files In Submission

Name	View Source	Status
smmt-20220930_cal.xml	Edgar Link	unprocessable
0001599298-22-000118-index-headers.html	Edgar Link	pending
0001599298-22-000118-index.html	Edgar Link	pending
0001599298-22-000118.txt	Edgar Link	pending
0001599298-22-000118-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
smmt-20220930_lab.xml	Edgar Link	unprocessable
smmt-20220930_pre.xml	Edgar Link	unprocessable
smmt-20220930_def.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smmt-20220930.htm	Edgar Link	pending
smmt-20220930.xsd	Edgar Link	pending
sum-ex311_20220930xduggan.htm	Edgar Link	pending
sum-ex312_20220930xzanganeh.htm	Edgar Link	pending
sum-ex313_20220930xdhingra.htm	Edgar Link	pending
sum-ex321_20220930x10q.htm	Edgar Link	pending
smmt-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMMT
Summit Therapeutics Inc. Stock $smmt

2022 Q4 Form 10-Q Financial Statement

#000159929822000118 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT Summit Therapeutics Inc. Stock $smmt

2022 Q4 Form 10-Q Financial Statement

#000159929822000118 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT
Summit Therapeutics Inc. Stock $smmt